Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Abstract

In patients with type 2 diabetes at high cardiovascular risk, empagliflozin was associated with slower progression of kidney disease and lower rates of clinically relevant renal events than was placebo when added to standard care. (Funded by the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance; EMPA-REG OUTCOME ClinicalTrials.gov number, NCT01131676.).

Keywords

EmpagliflozinMedicinePlaceboHazard ratioInternal medicineDiabetes mellitusAlbuminuriaRenal functionType 2 diabetesDiabetic nephropathyCreatinineKidney diseaseUrologySurgeryConfidence intervalEndocrinologyPathology

Affiliated Institutions

Related Publications

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman , Christoph Wanner , John M. Lachin +9 more

Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascul...

2015 New England Journal of Medicine 11369 citations

Empagliflozin in Patients with Chronic Kidney Disease

William G. Herrington , Natalie Staplin , Christoph Wanner +36 more

Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease o...

2022 New England Journal of Medicine 1959 citations

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker , Javed Butler , Gerasimos Filippatos +38 more

Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless...

2021 New England Journal of Medicine 4054 citations

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Milton Packer , Stefan D. Anker , Javed Butler +36 more

Among patients receiving recommended therapy for heart failure, those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure th...

2020 New England Journal of Medicine 4558 citations

Long-Term Stabilizing Effect of Angiotensin-Converting Enzyme Inhibition on Plasma Creatinine and on Proteinuria in Normotensive Type II Diabetic Patients

Mordchai Ravid

In normotensive patients with diabetes mellitus type II, the institution of angiotensin-converting enzyme inhibition during early stages of diabetic nephropathy results in long-...

1993 Annals of Internal Medicine 784 citations

Publication Info

Year: 2016
Type: article
Volume: 375
Issue: 4
Pages: 323-334
Citations: 3470
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

3470

OpenAlex

Cite This

APA Style

                            
                                
                                    Christoph Wanner, 
                                
                                    Silvio E. Inzucchi, 
                                
                                    John M. Lachin
                                
                                et al.
                            
                            (2016). 
                            Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. 
                            New England Journal of Medicine
                            , 375
                            (4)
                            , 323-334.
                            https://doi.org/10.1056/nejmoa1515920
                        

Identifiers

DOI: 10.1056/nejmoa1515920